Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCT05263895 | Registry Identifier | ClinicalTrials.gov |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to estimate the relative bioavailability of PF-07321332 in different formulations in healthy adult participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment A: PF-0732133/ritonavir | Active Comparator | PF-07321332 ritonavir |
|
| Treatment B: PF-07321332/ritonavir | Experimental | PF-07321332 ritonavir |
|
| Treatment C: PF-07321332/ritonavir | Experimental | PF-07321332 ritonavir |
|
| Treatment D: PF-07321332/ritonavir | Experimental | PF-07321332 ritonavir |
|
| Treatment E: PF-07321332 | Experimental | PF-07321332 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-07321332/ritonavir | Drug | PF-07321332 ritonavir will be administered as single dose orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (Clast) (AUClast) of Nirmatrelvir | AUClast for nirmatrelvir was calculated by Linear/Log trapezoidal method. Natural log-transformed AUClast for nirmatrelvir (slower dissolution tablets and large particle size tablets) was analyzed using a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect. Natural log-transformed AUClast for Nirmatrelvir (SDD suspension) was analyzed using a mixed effect model with sequence and treatment as fixed effects and participant within sequence as a random effect. | 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours postdose |
| Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Nirmatrelvir | AUCinf for nirmatrelvir was calculated by AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve. Natural log-transformed AUCinf for nirmatrelvir (slower dissolution tablets and large particle size tablets) was analyzed using a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect. Natural log-transformed AUCinf for Nirmatrelvir (SDD suspension) was analyzed using a mixed effect model with sequence and treatment as fixed effects and participant within sequence as a random effect. | 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours postdose |
| Maximum Plasma Concentration (Cmax) of Nirmatrelvir | Cmax for nirmatrelvir was observed directly from data. Natural log-transformed Cmax for nirmatrelvir (slower dissolution tablets and large particle size tablets) was analyzed using a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect. Natural log-transformed Cmax for Nirmatrelvir (SDD suspension) was analyzed using a mixed effect model with sequence and treatment as fixed effects and participant within sequence as a random effect. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs might arise from symptoms or other complaints reported to the investigator by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative), or they might arise from clinical findings of the investigator or other healthcare providers (clinical signs, test results, etc.). TEAEs were those with initial onset or increasing in severity after the first dose of study treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Clinical Research Unit - New Haven | New Haven | Connecticut | 06511 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37231296 | Derived | Sagawa K, Lin J, Jaini R, Di L. Physiologically-Based Pharmacokinetic Modeling of PAXLOVID with First-Order Absorption Kinetics. Pharm Res. 2023 Aug;40(8):1927-1938. doi: 10.1007/s11095-023-03538-5. Epub 2023 May 25. |
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
Twelve participants were enrolled to 1 of 6 sequences. Each participant participated in 5 study periods to receive 5 treatments: Treatment A: nirmatrelvir (commercial tablets)/ritonavir 300/100 mg; Treatment B: nirmatrelvir (slower dissolution tablets)/ritonavir 300/100 mg; Treatment C: nirmatrelvir (large particle size tablets)/ritonavir 300/100 mg; Treatment D: nirmatrelvir (spray dried dispersion [SDD] suspension)/ritonavir 300/100 mg; Treatment E: nirmatrelvir 300 mg (SDD suspension)
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Sequence 1 | Twelve participants were randomly assigned to 1 of 6 sequences. Each sequence included 2 participants who received 5 study treatments in 5 study periods. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg commercial tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 1. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg slower dissolution tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 2. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 3. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 4. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours) in Period 5. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Period 1 |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 8, 2022 | May 2, 2023 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| PF-07321332/ritonavir | Drug | PF-07321332 ritonavir will be administered as single oral dose orally. |
|
| PF-07321332/ritonavir | Drug | PF-07321332 ritonavir will be administered as single oral dose orally. |
|
| PF-07321332/ritonavir | Drug | PF-07321332 ritonavir will be administered as single oral dose orally. |
|
| PF-07321332 | Drug | PF-07321332 will be administered as single oral dose orally. |
|
| 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours postdose |
| Baseline up to 35 days after last dose of study intervention (up to 12 weeks) |
| Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | The laboratory abnormality parameters included Chemistry: bicarbonate (milliequivalents per liter [mEq/L]) <0.9 x lower limit of normal (LLN), urobilinogen (ehrlich units per deciliter [EU/dL]) >=1, and fibrinogen (milligram/deciliter [mg/dL]) >1.25 x baseline; Urinalysis: URINE hemoglobin (Scalar) >=1, only those categories in which at least 1 participant had data were reported. All the safety laboratory samples were collected following at least a 4 hour fast. Clinical laboratory evaluations only included treatments of nirmatrelvir SDD suspension/ritonavir 300/100 mg and nirmatrelvir SDD suspension 300 mg. No participant was evaluable for clinical laboratory evaluations for the other treatments. | Screening (from Day-28 to Day-2), Day-1 of Period 1 (before 1st dose) and Day4 of Period 5 (4 days after the last dose on study discharge day). Each treatment period was 4 days long (Day1 to Day4) with a minimum of 4 days washout between each period |
| Number of Participants With Vital Signs Abnormalities | Single supine blood pressure (BP) and pulse rate (PR) were measured with the participant's arm supported at the level of the heart and recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm (preferably the dominant arm) was used throughout the study. Participants were instructed not to speak during measurements. | Screening (D28-D2), D1 of Period 1 (before 1st dose), D1 hr 0,2,and 6 of each period, and D4 of Period 5 (4 days after the last dose on study discharge day). Each treatment Period was 4 days long (D1-D4) with a minimum 4 days washout between each period |
| Number of Participants With ECG Abnormalities | Standard 12-lead ECGs utilizing limb leads (with a 10 second rhythm strip) were collected. All scheduled ECGs were performed after the participant had rested quietly for at least 5 minutes in a supine position. | Screening (from D-28 to D-2), D1, hr0 of Period 1 (before 1st dose) and D4 of Period 5 (4 days after last dose on study discharge day). Each treatment period was 4 days long (D1 to D4) with a minimum of 4 days washout between each period |
| Number of Participants With Physical Examination Abnormalities | A complete PE included, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination included, at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant reported symptoms. | Screening (from Day-28 to Day-2), Day-1 of Period 1 (before 1st dose. Each treatment period was 4 days long (Day1 to Day4) with a minimum of 4 days washout between each period |
| FG001 | Sequence 2 | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg slower dissolution tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 1. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 2. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg commercial tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 3. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 4. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours) in Period 5. |
| FG002 | Sequence 3 | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 1. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg commercial tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 2. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg slower dissolution tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 3. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 4. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours) in Period 5. |
| FG003 | Sequence 4 | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg commercial tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 1. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 2. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg slower dissolution tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 3. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours) in Period 4. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 5. |
| FG004 | Sequence 5 | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg slower dissolution tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 1. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg commercial tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 2. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 3. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours) in Period 4. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 5. |
| FG005 | Sequence 6 | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 1. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg slower dissolution tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 2. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg commercial tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 3. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours) in Period 4. On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours) in Period 5. |
| COMPLETED |
|
| NOT COMPLETED |
|
| Period 2 |
|
| Period 3 |
|
| Period 4 |
|
| Period 5 |
|
All participants who took at least 1 dose of study intervention.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | All Participants | All participants enrolled in this study, "Enrolled" meant a participant's agreement to participate in a clinical study following completion of the informed consent process and screening. Potential participants who were screened for the purpose of determining eligibility for the study, but did not participate in the study, were not considered enrolled, unless otherwise specified by the protocol. A participant was considered enrolled if the informed consent was not withdrawn prior to participating in any study activity after screening. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median | Full Range | Years |
| ||||||||||||||||||||||
| Age, Customized | Number | Participants |
| |||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Race | Number | Participants |
| ||||||||||||||||||||||
| Race/Ethnicity, Customized | Ethnicity | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (Clast) (AUClast) of Nirmatrelvir | AUClast for nirmatrelvir was calculated by Linear/Log trapezoidal method. Natural log-transformed AUClast for nirmatrelvir (slower dissolution tablets and large particle size tablets) was analyzed using a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect. Natural log-transformed AUClast for Nirmatrelvir (SDD suspension) was analyzed using a mixed effect model with sequence and treatment as fixed effects and participant within sequence as a random effect. | All participants who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of primary interest were reported. | Posted | Geometric Mean | Geometric Coefficient of Variation | nanogram*hour per milliliter (ng*hr/mL) | 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours postdose |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Nirmatrelvir | AUCinf for nirmatrelvir was calculated by AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve. Natural log-transformed AUCinf for nirmatrelvir (slower dissolution tablets and large particle size tablets) was analyzed using a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect. Natural log-transformed AUCinf for Nirmatrelvir (SDD suspension) was analyzed using a mixed effect model with sequence and treatment as fixed effects and participant within sequence as a random effect. | All participants who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of primary interest were reported. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours postdose |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Maximum Plasma Concentration (Cmax) of Nirmatrelvir | Cmax for nirmatrelvir was observed directly from data. Natural log-transformed Cmax for nirmatrelvir (slower dissolution tablets and large particle size tablets) was analyzed using a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect. Natural log-transformed Cmax for Nirmatrelvir (SDD suspension) was analyzed using a mixed effect model with sequence and treatment as fixed effects and participant within sequence as a random effect. | All participants who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of primary interest were reported. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng/mL | 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours postdose |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs might arise from symptoms or other complaints reported to the investigator by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative), or they might arise from clinical findings of the investigator or other healthcare providers (clinical signs, test results, etc.). TEAEs were those with initial onset or increasing in severity after the first dose of study treatment. | All participants who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received. | Posted | Count of Participants | Participants | Baseline up to 35 days after last dose of study intervention (up to 12 weeks) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | The laboratory abnormality parameters included Chemistry: bicarbonate (milliequivalents per liter [mEq/L]) <0.9 x lower limit of normal (LLN), urobilinogen (ehrlich units per deciliter [EU/dL]) >=1, and fibrinogen (milligram/deciliter [mg/dL]) >1.25 x baseline; Urinalysis: URINE hemoglobin (Scalar) >=1, only those categories in which at least 1 participant had data were reported. All the safety laboratory samples were collected following at least a 4 hour fast. Clinical laboratory evaluations only included treatments of nirmatrelvir SDD suspension/ritonavir 300/100 mg and nirmatrelvir SDD suspension 300 mg. No participant was evaluable for clinical laboratory evaluations for the other treatments. | Participants with at least 1 observation of the given laboratory test while on study treatment or during lag time. | Posted | Count of Participants | Participants | Screening (from Day-28 to Day-2), Day-1 of Period 1 (before 1st dose) and Day4 of Period 5 (4 days after the last dose on study discharge day). Each treatment period was 4 days long (Day1 to Day4) with a minimum of 4 days washout between each period |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Vital Signs Abnormalities | Single supine blood pressure (BP) and pulse rate (PR) were measured with the participant's arm supported at the level of the heart and recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm (preferably the dominant arm) was used throughout the study. Participants were instructed not to speak during measurements. | All participants who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received. | Posted | Count of Participants | Participants | No | Screening (D28-D2), D1 of Period 1 (before 1st dose), D1 hr 0,2,and 6 of each period, and D4 of Period 5 (4 days after the last dose on study discharge day). Each treatment Period was 4 days long (D1-D4) with a minimum 4 days washout between each period |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With ECG Abnormalities | Standard 12-lead ECGs utilizing limb leads (with a 10 second rhythm strip) were collected. All scheduled ECGs were performed after the participant had rested quietly for at least 5 minutes in a supine position. | All participants who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received. | Posted | Count of Participants | Participants | Screening (from D-28 to D-2), D1, hr0 of Period 1 (before 1st dose) and D4 of Period 5 (4 days after last dose on study discharge day). Each treatment period was 4 days long (D1 to D4) with a minimum of 4 days washout between each period |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Physical Examination Abnormalities | A complete PE included, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination included, at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant reported symptoms. | All participants who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received. | Posted | Count of Participants | Participants | Screening (from Day-28 to Day-2), Day-1 of Period 1 (before 1st dose. Each treatment period was 4 days long (Day1 to Day4) with a minimum of 4 days washout between each period |
|
Baseline up to 35 days after last dose of study intervention (up to 12 weeks)
The same event may appear as both an AE and an SAE. An event may be categorized as serious in 1 participant and as non-serious in another participant, or 1 participant may have experienced both a serious and non-serious event during the study. Total number at risk below refers to the number of participants evaluable for SAEs or AEs.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Nirmatrelvir (Commercial Tablets)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg commercial tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). | 0 | 12 | 0 | 12 | 4 | 12 |
| EG001 | Nirmatrelvir (Slower Dissolution Tablets)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg slower dissolution tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). | 0 | 12 | 0 | 12 | 1 | 12 |
| EG002 | Nirmatrelvir (Large Particle Size Tablets)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). | 0 | 12 | 0 | 12 | 3 | 12 |
| EG003 | Nirmatrelvir (SDD Suspension)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). | 0 | 12 | 0 | 12 | 0 | 12 |
| EG004 | Nirmatrelvir (SDD Suspension) 300 mg | On Day, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours). | 0 | 12 | 0 | 12 | 1 | 12 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal pain | Gastrointestinal disorders | MedDRA v25.0 | Non-systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA v25.0 | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA v25.0 | Non-systematic Assessment |
| |
| Dysgeusia | Nervous system disorders | MedDRA v25.0 | Non-systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA v25.0 | Non-systematic Assessment |
| |
| Haematoma | Vascular disorders | MedDRA v25.0 | Non-systematic Assessment |
| |
| Phlebitis | Vascular disorders | MedDRA v25.0 | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Mar 11, 2022 | May 2, 2023 | SAP_001.pdf |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000719967 | nirmatrelvir and ritonavir drug combination |
| C000718217 | nirmatrelvir |
Not provided
Not provided
Not provided
| 45-64 years |
|
| >=65 years |
|
| Black or African American, White |
|
| Ratio of Adjusted Geometric Means |
| 102.78 |
| 2-Sided |
| 90 |
| 90.65 |
| 116.53 |
| Other |
| Test: Nirmatrelvir (SDD suspension)/ritonavir 300/100 mg Reference: Nirmatrelvir (commercial tablets)/ritonavir 300/100 mg | Ratio of Adjusted Geometric Means | 138.15 | 2-Sided | 90 | 118.03 | 161.69 | Other |
| Test: Nirmatrelvir (SDD suspension) 300 mg Reference: Nirmatrelvir (commercial tablets)/ritonavir 300/100 mg | Ratio of Adjusted Geometric Means | 30.8 | 2-Sided | 90 | 25.70 | 35.20 | Other |
On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg slower dissolution tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG002 | Nirmatrelvir (Large Particle Size Tablets)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG003 | Nirmatrelvir (SDD Suspension)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG004 | Nirmatrelvir (SDD Suspension) 300 mg | On Day, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours). |
|
|
|
| OG002 | Nirmatrelvir (Large Particle Size Tablets)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG003 | Nirmatrelvir (SDD Suspension)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG004 | Nirmatrelvir (SDD Suspension) 300 mg | On Day, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours). |
|
|
|
| OG002 | Nirmatrelvir (Large Particle Size Tablets)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG003 | Nirmatrelvir (SDD Suspension)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG004 | Nirmatrelvir (SDD Suspension) 300 mg | On Day, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours). |
|
|
On Day, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours). |
|
|
| OG002 | Nirmatrelvir (Large Particle Size Tablets)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG003 | Nirmatrelvir (SDD Suspension)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG004 | Nirmatrelvir (SDD Suspension) 300 mg | On Day, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours). |
|
|
| OG002 |
| Nirmatrelvir (Large Particle Size Tablets)/Ritonavir 300/100 mg |
On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG003 | Nirmatrelvir (SDD Suspension)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG004 | Nirmatrelvir (SDD Suspension) 300 mg | On Day, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours). |
|
|
| OG002 | Nirmatrelvir (Large Particle Size Tablets)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as 2 × 150 mg larger particle size tablets, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG003 | Nirmatrelvir (SDD Suspension)/Ritonavir 300/100 mg | On Day 1, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally with ritonavir 100 mg (as 1 × 100 mg tablet) starting at approximately 0800 hours (plus or minus 2 hours). |
| OG004 | Nirmatrelvir (SDD Suspension) 300 mg | On Day, following an overnight fast of at least 10 hours, participants received nirmatrelvir 300 mg as SDD suspension, administered orally without ritonavir starting at approximately 0800 hours (plus or minus 2 hours). |
|
|